Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Non-Current Assets (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Non-Current Assets for 7 consecutive years, with $31.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 107.56% to $31.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$310.8 million, a 19.19% increase, with the full-year FY2024 number at $34.7 million, up 421.42% from a year prior.
  • Non-Current Assets was $31.0 million for Q3 2025 at Pliant Therapeutics, down from $33.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $34.7 million in Q4 2024 to a low of -$410.0 million in Q3 2024.
  • A 5-year average of -$32.4 million and a median of $9.2 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 3572.6% in 2022, then soared 421.42% in 2024.
  • Pliant Therapeutics' Non-Current Assets stood at $11.8 million in 2021, then decreased by 12.5% to $10.3 million in 2022, then tumbled by 35.43% to $6.7 million in 2023, then skyrocketed by 421.42% to $34.7 million in 2024, then decreased by 10.59% to $31.0 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Non-Current Assets are $31.0 million (Q3 2025), $33.6 million (Q1 2025), and $34.7 million (Q4 2024).